Study of the acquisition of sensitivity to paclitaxel plus cetuximab by the addition of low-dose proteasome inhibitor

M Yoda, K Sakuma, T Kii, A Tanaka - Anticancer Research, 2022 - ar.iiarjournals.org
Background/Aim: Although paclitaxel plus cetuximab for recurrent/metastatic oral squamous
cell carcinoma (OSCC) has a relatively high success rate, many cases are refractory. We …

[HTML][HTML] Prognostic evaluation of oral squamous cell carcinoma based on pleiotrophin, urokinase plasminogen activator, and glycoprotein nonmetastatic melanoma …

Y Ma, Y Liu, H Meng - Medicine, 2023 - journals.lww.com
This study investigated the expression of pleiotrophin (PTN), urokinase plasminogen
activator (uPA), and glycoprotein nonmetastatic melanoma protein B (GPNMB) in oral …

Oxymatrine Inhibits Malignant Behaviors of Breast Cancer Cells by Inhibiting miR-188 Expression to Up-Regulate Phosphatase and Tensin Homolog (PTEN)

X Wang, Y Hu, D Chen, L Cheng, L Yu… - Journal of Biomaterials …, 2023 - ingentaconnect.com
Oxymatrine has been applied to anti-cancer therapies for various cancers. The present study
aimed to investigate the potential impact of miR-188 on breast cancer (BC) cell progression …